Evidence map›Paper›PMID 30805315›Full record

ArticleOncolytic virotherapy2019

A cautionary note on the selectivity of oncolytic poxviruses.

Bingtao Tang, Zong Sheng Guo, David L Bartlett, Jia Liu, Grant McFadden, Joanna L Shisler, Edward J Roy

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncolytic virotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Molecular therapy oncolytics · 2020
    Article
  14. Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020
    Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Bingtao TangDepartment of Molecular and Integrative Physiology, University of Illinois Urbana-Champaign, Urbana, IL, USA, eroy@illinois.edu.
Zong Sheng GuoDepartment of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
David L BartlettDepartment of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Jia LiuDepartment of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Grant McFaddenBiodesign Institute, Arizona State University, Tempe, AZ, USA.
Joanna L ShislerDepartment of Microbiology, University of Illinois Urbana-Champaign, Urbana, IL USA.
Edward J RoyDepartment of Molecular and Integrative Physiology, University of Illinois Urbana-Champaign, Urbana, IL, USA, eroy@illinois.edu.
University of Illinois Urbana-Champaign · USUniversity of Pittsburgh · USArizona State University · USUniversity of Arkansas for Medical Sciences · US

Funding

Studies in Poxvirus Evasion of SAMD9 PathwayR01AI139106 · NIAID · UNIV OF ARKANSAS FOR MED SCIS · PI LIU, JIA · 2019 to 2023
$1.9M
Characterization of Antiviral Functions of Sterile Alpha Motif-Containing DomainK22AI099184 · NIAID · UNIV OF ARKANSAS FOR MED SCIS · PI LIU, JIA · 2013 to 2014
$268k
NIAID NIH HHS K22 AI099184NIAID NIH HHS R01 AI139106
6 · The paper itself

Abstract

backgroundOncolytic viruses selectively infect cancer cells while avoiding infection of normal cells. Usually, selectivity is demonstrated by injecting a virus into tumor-bearing mice and observing infection and lysis of tumor cells without infection of other tissues. The general view is that this selectivity is due to tropisms of the virus. However, apparent selectivity could be due to accessibility. For example, intravenously injected virus may not gain access to cells within the central nervous system (CNS) because of the blood-brain barrier. PURPOSE: We tested the CNS safety of two oncolytic poxviruses that have been demonstrated to be safe for treatment of peripheral tumors (vaccinia virus vvDD-IL15-Rα and myxoma virus vMyx-IL15Rα-tdTr).

methodsTwo poxviruses were tested for selectivity in vitro and in vivo.

resultsBoth viruses infected glioma cells in vitro. In vivo, both viruses infected glioma cells and did not infect neurons when injected into a tumor or into the normal striatum. However, viral gene expression was observed in ependymal cells lining the ventricles, implying that these poxviruses were not as selective as originally predicted. For vvDD-IL15-Rα, some tumor-bearing mice died soon after virus treatment. If the same titer of vvDD-IL15-Rα was injected directly into the lateral cerebral ventricle of nontumor-bearing mice, it was uniformly fatal. Infection of ependymal cells, subventricular cells, and meninges was widespread. On the other hand, vMyx-IL15Rα-tdTr only transiently infected ependymal cells and was safe even when injected directly into the lateral cerebral ventricles. The two poxviruses also differed in their infection of dendritic cells; vvDD-IL15-Rα infected dendritic cells and lysed them but vMyx-IL15Rα-tdTr did not.

conclusionVaccinia virus vvDD-IL15-Rα is very promising for treating cancer types outside of the brain. However, for cancers located within the brain, myxoma virus vMyx-IL15Rα-tdTr offers a safer alternative.

Indexed as

central nervous system toxicitygliomaoncolytic virussafety

Identifiers

PMID30805315
PMCPMC6375109
OpenAlexW2912938597

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.